The Global RNA Therapy Clinical Trials Market Size is valued at 2.45 billion in 2022 and is predicted to reach 3.32 billion by the year 2031 at a 3.6% CAGR during the forecast period for 2023-2031.
The process of testing and evaluating the safety and effectiveness of therapeutic interventions based on RNA molecules is referred to as RNA therapy clinical trials. RNA therapy is a large group of treatments that use various forms of RNA molecules to target and modulate gene expression, such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides. Various factors influence the market dynamics for RNA treatment clinical trials. As interest in and investment in RNA therapy has grown, so has competition among businesses developing RNA-based medications. Established pharmaceutical businesses, as well as startups and biotech companies, entered the industry, spurring innovation and clinical trial activity.
However, due to the pandemic, many active RNA treatment clinical trials were either halted or delayed. Clinical study activities were halted due to lockdowns, travel restrictions, and worries about the safety of trial participants and staff.
Competitive Landscape:
Some of the RNA Therapy Clinical Trials Market players are:
- IQVIA
- ICON Plc
- Laboratory Corporation of America Holdings
- Charles River Laboratories International, Inc.
- PAREXEL International Corp.
- Syneos Health
- Medpace Holdings, Inc.
- PPD Inc.
- Novotech
- Veristat, LLC
Market Segmentation:
The RNA Therapy Clinical Trials Market is segmented on the basis of modality, clinical trials, and therapeutic areas. Modality segment includes RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi. The clinical trials segment includes Phase I, Phase II, Phase III, and Phase IV. By therapeutic areas, the market is segmented into Rare Diseases, Anti-infective, anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular, Respiratory, Sensory, and Others.
Based On The Product, The Messenger RNA Segment Is Accounted As A Major Contributor In The RNA Therapy Clinical Trials Market
The Messenger RNA category is expected to hold a major share of the global RNA Therapy Clinical Trials Market in 2022. The COVID-19 pandemic pushed the development and deployment of mRNA-based vaccines, particularly Pfizer-BioNTech and Moderna's COVID-19 vaccines. Because of the effectiveness of these mRNA vaccines, mRNA technology has received attention and demonstrated potential in the fight against infectious diseases. Furthermore, mRNA therapies have various potential applications in a variety of disease conditions. They can be used to encode specific proteins that produce therapeutic antibodies, trigger an immune response, or restore protein function.
Phase II Segment Witnessed Growth At A Rapid Rate
The Phase II segment is projected to grow at a rapid rate in the global RNA Therapy Clinical Trials Market. Increasing R&D investment and increasing non-industry-sponsored and industry-sponsored phase II clinical studies are important contributors to the segment's growth. Phase 2 studies enable the optimal dose and dosing schedule for RNA treatments to be determined.
In The Region, The North American RNA Therapy Clinical Trials Market Holds A Significant Revenue Share
The North American RNA Therapy Clinical Trials Market is expected to report the highest market share in terms of revenue in the near future. This is due to the early acceptance of RNA therapeutics, a strong research infrastructure, a favorable regulatory environment, and a large biotechnology and pharmaceutical industry. Furthermore, numerous RNA therapies have previously acquired FDA approval, and many are currently through various phases of clinical research to demonstrate their efficacy for a variety of illnesses.
Over the projection period, Asia Pacific is expected to increase significantly. Academic institutions, research organizations, and biotech firms are actively involved in RNA-based research in countries such as China, Japan, South Korea, and Singapore, resulting in an expanding pipeline of potential RNA therapeutics and an increase in the number of clinical studies in the field.
RNA Therapy Clinical Trials Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 2.45 Bn |
|
Revenue Forecast In 2031 |
USD 3.32 Bn |
|
Growth Rate CAGR |
CAGR of 3.6 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Modality, Clinical Trials, And Therapeutic Areas |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
IQVIA; ICON Plc; Laboratory Corporation of America Holdings; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Syneos Health; Medpace Holdings, Inc.; PPD Inc.; Novotech; Veristat, LLC. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
